Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.55 |
| ▸ | JAK3 | P52333 | 12/20 | 0.55 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.46 |
| ▸ | SYK | P43405 | 2/20 | 0.45 |
| ▸ | CD63 | P08962 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15210695 | 0.87 | JAK2 (0.58) | JAK2JAK3PLK1PTK2KDR | |
| SCHEMBL15210703 | 0.86 | JAK2 (0.73) | JAK2JAK3FLT3AURKAKIT | |
| SCHEMBL15210810 | 0.86 | JAK2 (0.58) | JAK2JAK3PLK1PTK2KDR | |
| SCHEMBL21968 | 0.86 | JAK2 (0.54) | JAK2JAK3PTK2KDR | |
| SCHEMBL21816 | 0.85 | CHEK1 (0.49) | JAK2JAK3PLK1FLT3AURKA | |
| SCHEMBL15221130 | 0.84 | JAK2 (0.61) | JAK2JAK3IRAK4PTK2SYK | |
| SCHEMBL20773 | 0.84 | JAK2 (0.53) | JAK2JAK3PTK2 | |
| SCHEMBL16394542 | 0.83 | JAK2 (0.65) | JAK2JAK3FLT3KITIRAK4 | |
| SCHEMBL15208269 | 0.82 | TP53 (0.46) | JAK2JAK3PLK1FLT3AURKA | |
| SCHEMBL21175 | 0.81 | FLT3 (0.51) | JAK2JAK3PLK1FLT3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025058-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-22 | — | — | US | claimed |
| EP-2817310-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4]TRIAZOLO [1, 5 -A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | Merck Patent GmbH (DE) | 2014-12-31 | — | — | EP | claimed |
| WO-2013124026-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2013-08-29 | — | — | WO | claimed |
| EP-2817310-B1 | 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2018-03-21 | — | — | EP | disclosed |
| EP-2817310-B1 | 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2018-03-21 | — | — | EP | disclosed |
| US-9120804-B2 | 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-9120804-B2 | 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-9120804-B2 | 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-20150025058-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-20150025058-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025058-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | SYK, EIF2AK4, BTK | JAK2 29/4885JAK3 127/4885PLK1 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.